Filing Flows › Foghorn Therapeutics (FHTX) › Q1 2026
Foghorn Therapeutics (FHTX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Foghorn Therapeutics (FHTX) reported revenue of $3.3M for the first quarter 2026 (Q1 2026), -45% from a year earlier and -65% from the quarter before. Operating margin was -660.3%, net loss $19.9M (608.4% of revenue).
Foghorn Therapeutics, Q1 2026: revenue $3.3M (-45% year over year), operating margin -660.3%, net loss $19.9M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | -65% | -45% |
| Operating profit | −$21.6M | — | — |
| Net earnings | −$19.9M | — | — |
| Operating cash flow | −$25.3M | — | — |
What changed
Revenue was $3.3M in Q1 2026, down 45% year over year and down 65% from the previous quarter.
Operating costs exceeded revenue by $21.6M, an operating margin of -660.3%. Total costs fell 14% while revenue fell 45%. The quarter ended with a net loss of $19.9M, narrower than the previous quarter's $21.7M loss.
Operating cash flow was −$25.3M. Non-cash charges added back $238K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $8.0M.
Questions
What was Foghorn Therapeutics' revenue in the first quarter 2026?
Foghorn Therapeutics (FHTX) reported revenue of $3.3M for the first quarter 2026 (Q1 2026), -45% from a year earlier and -65% from the quarter before.
Was Foghorn Therapeutics profitable in the first quarter 2026?
Operating loss was $21.6M (-660.3% of revenue) and net loss $19.9M.